Charles River Laboratories International, Inc. revised financial guidance for 2024. For the period, the company expects revenue growth to be 1.0% to 4.0% compared to previous guidance of 1.0% to 4.0%, organic revenue growth of 0.0% to 3.0% compared to previous guidance of 0.0% to 3.0%, GAAP EPS estimate $7.60 to $8.10 compared to previous guidance of $7.90-$8.40.
Charles River Laboratories International, Inc.
Equities
CRL
US1598641074
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
208.4 USD | -0.61% | -4.04% | -11.83% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.83% | 10.74B | |
+43.36% | 54.63B | |
-5.31% | 39.92B | |
+37.52% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B |
- Stock Market
- Equities
- CRL Stock
- News Charles River Laboratories International, Inc.
- Charles River Laboratories International, Inc. Revises Financial Guidance for 2024